Pentax rejects Ambu's claims of head start

The pandemic has created a market frenzy for single-use bronchoscopes. Pentax Medical denies that Ambu has a head start over its closest international rivals.

BY ULRICH QUISTGAARD, TRANSLATED BY DANIEL INGEMANN KROIER PEDERSEN

Published: 02.09.21 at 07:13

According to Pentax Medical, the pandemic has accelerated the demand for medical products that can be used without the risk of infection, increasing the competition on the global market for single-use endoscopes.

Gerald Bottero, president of the Japanese Pentax Medical, one of the closest competitors to Danish firm Ambu, writes the following in an email to MedWatch:

Already a subscriber? Log in.

Read the whole article

Get 14 days free access.
No credit card required.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

"Real world" patient data documents the long-term effects of ALK vaccines

Data from ALK's React study, which is a retrospective real-world evidence study including more than 92,000 patients with respiratory allergies, have just been published in the journal The Lancet Regional Health – Europe. | Foto: ALK / PR

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers.